Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Author information

1
Cedars Sinai Medical Center, Los Angeles, California 90048, USA.

Abstract

OBJECTIVE:

The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.

PARTICIPANTS:

The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer.

EVIDENCE:

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.

CONSENSUS PROCESS:

One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.

CONCLUSIONS:

Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

PMID:
21296991
DOI:
10.1210/jc.2010-1692
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center